公开(公告)号：EP2970288A1

公开(公告)日：2016-01-20

申请号：EP13812337.7

申请日：2013-12-06

申请人： Vertex Pharmaceuticals Incorporated

发明人： CHARRIER, Jean-Damien ,  DAVIS, Chris ,  DURRANT, Steven ,  FRAYSSE, Damien ,  JIMENEZ, Juan-Miguel ,  KAY, Dave ,  KNEGTEL, Ronald ,  O'DONNELL, Michael ,  PIERARD, Francoise ,  PINDER,Joanne ,  STORCK, Pierre-Henri ,  TWIN, Heather

IPC分类号： C07D487/04 ,  A61K31/437 ,  A61P35/00

CPC分类号： C07D487/04 ,  A61K31/437 ,  C07D491/107 ,  C07D519/00

摘要： The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I); or a pharmaceutically acceptable salt, wherein the variables R
1 , R
2 , R
3 , and R
4 are as defined herein.

摘要翻译： 本发明涉及用作ATR蛋白激酶抑制剂的化合物。 本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用这些化合物的方法，例如生物学和病理学现象中的激酶研究; 这种激酶介导的细胞内信号转导途径的研究; 和新的激酶抑制剂的比较评估。 本发明的化合物具有式（I）; 或其药学上可接受的盐，其中变量R 1，R 2，R 3和R 4如本文所定义。